

2. *Blumberg Bank, L.P.* Seguin, Texas; to become a bank holding company by acquiring 48 percent of the voting shares of Seguin State Bank & Trust Company, Seguin, Texas.

Board of Governors of the Federal Reserve System, March 16, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95-7012 Filed 3-21-95; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Agency Information Collection Under OMB Review

Under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35), the Administration for Children and Families (ACF) has submitted to the Office of Management and Budget (OMB) a request for the continued use of an information collection titled: ACF-231-Aid To Families With Dependent Children Financial Report; Expenditures and Estimates.

Addresses: Copies of the request for approval may be obtained from Robert A. Sargis of the Office of Information Systems Management, ACF, by calling (202) 690-7275.

Consideration will be given to comments and suggestions received within 60 days of publication. Written comments and recommendations for the proposed information should be sent directly to the following: Wendy Taylor, Office of Information and Regulatory Affairs, Office of Management and Budget, Docket Library, Room 10102, 725 17th Street, N.W., Washington, D.C. 20503, (202) 395-7316.

Information on Document

Title: ACF-231 AID TO FAMILIES WITH DEPENDENT CHILDREN FINANCIAL REPORT

OMB No.: 0970-0032

Description: The information collected is required by the Social Security Act to collect program and financial data under the AFDC program. The State agency provides a quarterly estimate of the total amount and the Federal share of expenditures to be made in administering the AFDC programs.

Respondents: State governments
Annual Number of Respondents: 54 sites

Number of responses per respondent: 6

Total annual responses: 324 sites

Hours per response: 3.5

Total Burden Hours: 1,134

Dated: March 16, 1995.

Roberta Katson,

Acting Director, Office of Information Resource Management.

[FR Doc. 95-7055 Filed 3-21-95; 8:45 am]

BILLING CODE 4184-01-M

Centers for Disease Control and Prevention (CDC)

The National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) Will Convene the Following Meeting Sponsored by the Division of Environmental Health Laboratory Sciences

Name: Development of Innovative Technology for Measurement of Lead in Blood: Meeting of Grant Recipients and Cooperative Research and Development Agreement (CRADA) Partners.

Time and date: 8:30 a.m.-11 a.m., May 20, 1995.

Place: Terrace Garden Inn-Buckhead, 3405 Lenox Road, NE, Atlanta, Georgia 30326.

Status: Open to the public, limited only by space available.

Purpose: The primary purpose of this meeting is to brief the grantees and CDC's CRADA partners about CDC expectations for the grant and CRADA program, to encourage collaboration among grantees and CRADA partners and to review progress toward the objectives of the program.

Matters to be discussed: Topics to be discussed include objectives of the CDC grant and CRADA program for the development of innovative technology for the measurement of lead in blood, impact of the Clinical Laboratory Improvement Act on the technology, and an overview of each grantee and CRADA organization.

Agenda items are subject to change as priorities dictate.

Contact person for more information: Robert L. Jones, Ph.D., Supervisory Research Chemist, Nutritional Biochemistry Branch, Division of Environmental Health Laboratory Sciences, (F18), NCEH, CDC, 4770 Buford Highway, NE, Chamblee, Georgia 30341-3724, telephone 404/488-7991.

Written comments are welcome and should be received by the contact person no later than May 10, 1995. Persons wishing to make oral comments at the meeting should notify the contact person in writing or by telephone no later than May 10, 1995. All requests to make oral comments should contain the name, address, telephone number, and organizational affiliation of the presenter. Depending on the time available and the number of requests to make oral comments, it may be necessary to limit the time of each presenter.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-6997 Filed 3-21-95; 8:45 am]

BILLING CODE 4163-18-M

Food and Drug Administration

Advisory Committees; Notice of Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1-800-741-8138 or 301-443-0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETINGS: The following advisory committee meetings are announced:

Drug Abuse Advisory Committee

Date, time, and place. April 6 and 7, 1995, 8 a.m., Parklawn Bldg., conference rooms D and E, 5600 Fishers Lane, Rockville, MD.

Type of meeting and contact person. Closed committee deliberations, April 6, 1995, 8 a.m. to 5 p.m.; open public hearing, April 7, 1995, 8 a.m. to 9 a.m., unless public participation does not last that long; open committee discussion, 9 a.m. to 4 p.m.; Stephen P. Pollitt, Center for Drug Evaluation and Research (HFD-9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), Drug Abuse Advisory Committee, code 12535.

General function of the committee.

The committee advises on the scientific and medical evaluation of information gathered by the Department of Health and Human Services and the Department of Justice on the safety,